In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (flobetapir F 18)

…, HF Kung, AD Joshi, DM Skovronsky… - Journal of nuclear …, 2010 - Soc Nuclear Med
An 18 F-labeled PET amyloid-β (Aβ) imaging agent could facilitate the clinical evaluation of
late-life cognitive impairment by providing an objective measure for Alzheimer disease (AD) …

Use of florbetapir-PET for imaging β-amyloid pathology

…, EM Reiman, SP Zehntner, DM Skovronsky… - Jama, 2011 - jamanetwork.com
Context The ability to identify and quantify brain β-amyloid could increase the accuracy of a
clinical diagnosis of Alzheimer disease. Objective To determine if florbetapir F 18 positron …

[HTML][HTML] Donanemab in early Alzheimer's disease

…, SP Salloway, DM Skovronsky - … England Journal of …, 2021 - Mass Medical Soc
Background A hallmark of Alzheimer’s disease is the accumulation of amyloid-β (Aβ)
peptide. Donanemab, an antibody that targets a modified form of deposited Aβ, is being …

[HTML][HTML] Protein kinase C-dependent α-secretase competes with β-secretase for cleavage of amyloid-β precursor protein in the trans-Golgi network

DM Skovronsky, DB Moore, ME Milla, RW Doms… - Journal of Biological …, 2000 - ASBMB
The release of amyloidogenic amyloid-β peptide (Aβ) from amyloid-β precursor protein (APP)
requires cleavage by β- and γ-secretases. In contrast, α-secretase cleaves APP within the …

[HTML][HTML] Bamlanivimab plus etesevimab in mild or moderate Covid-19

…, P Klekotka, L Shen, DM Skovronsky - … England Journal of …, 2021 - Mass Medical Soc
Background Patients with underlying medical conditions are at increased risk for severe
coronavirus disease 2019 (Covid-19). Whereas vaccine-derived immunity develops over time, …

Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial

…, C Ritchie, DA Brooks, M Mintun, DM Skovronsky… - Jama, 2023 - jamanetwork.com
Importance There are limited efficacious treatments for Alzheimer disease. Objective To assess
efficacy and adverse events of donanemab, an antibody designed to clear brain amyloid …

Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial

…, J Sabo, DR Patel, P Klekotka, L Shen, DM Skovronsky - Jama, 2021 - jamanetwork.com
Importance Coronavirus disease 2019 (COVID-19) continues to spread rapidly worldwide.
Neutralizing antibodies are a potential treatment for COVID-19. Objective To determine the …

[HTML][HTML] SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19

…, DR Patel, P Klekotka, DM Skovronsky - … England Journal of …, 2021 - Mass Medical Soc
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes
coronavirus disease 2019 (Covid-19), which is most frequently mild yet can be severe and life-…

Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study

…, M Lu, MA Mintun, DM Skovronsky - The Lancet …, 2012 - thelancet.com
Background Results of previous studies have shown associations between PET imaging of
amyloid plaques and amyloid-β pathology measured at autopsy. However, these studies …

Imaging of amyloid β in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism

…, HP Kung, W Zhang, MP Kung, D Skovronsky… - The Lancet …, 2008 - thelancet.com
Background Amyloid-β (Aβ) plaque formation is a hallmark of Alzheimer's disease (AD) and
precedes the onset of dementia. Aβ imaging should allow earlier diagnosis, but clinical …